USFDA gives tentative nod for ARV oral, Dolutegravir

"This option will help in strict compliance and adherence in the HIV treatment and benefits caretakers.”

79
USFDA Approval
USFDA Approval

Last Updated on October 6, 2024 by The Health Master

Laurus Labs announced the receipt of the USFDA tentative approval of their Oral Dispersible Film (ODF) Dolutegravir 5mg and 10mg for paediatric ARV treatment.

A company release informed, “This paediatric drug administration through Oral Dispersible Film technology developed by Laurus Labs will simplify the drug administration in children.”

“It will help in bringing a significant benefit in compliance with ARV medication in paediatric HIV treatment.”

“Laurus Labs was also the first generic approved company for a fixed dose combination of Abacavir/Dolutegravir/Lamivudine 600/50/300 mg, which is being used to treat adult HIV patients for second-line treatment.”

Commenting on the USFDA approval, Dr Satyanarayana Chava, Founder and CEO, Laurus Labs, said, “We are happy to receive the USFDA tentative approval for the World’s First Paediatric ARV drug Dolutegravir 5mg and 10mg, Oral Dispersible Film.”

USFDA gives approval for next generation Pneumococcal Vaccine

USFDA gives approval for this ALS drug

USFDA gives nod for Nitrofurantoin Oral Suspension USP

USFDA gives approval for Icosapent Ethyl Capsules

USFDA gives approval for Metoprolol Tartrate tablet

USFDA gives approval for Roflumilast Tablets 250 mcg

For informative videos by The Health Master, click on the below YouTube icon:

YouTube Icon

For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:

YouTube Icon

For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:

YouTube Icon

For informative videos on consumer awareness, click on the below YouTube icon:

YouTube Icon
Telegram
WhatsApp
Facebook
LinkedIn
YouTube Icon
Google-news